Clinical Trial Update: A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of LY2181308 for advanced hepatocellular carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LY2181308

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN